Drug Profile

NBI 921352

Alternative Names: NBI-921352; XEN 901

Latest Information Update: 25 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xenon Pharmaceuticals
Developer Neurocrine Biosciences; Xenon Pharmaceuticals
Class Antiepileptic drugs; Small molecules
Mechanism of Action Nav1.6 voltage-gated sodium channel inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Epilepsy
New Molecular Entity Yes

Highest Development Phases

Phase II Epilepsy
Discontinued Dravet syndrome; Seizures

Most Recent Events

31 Dec 2024 Patent issued for NBI 921352 in Foreign jurisdictions
31 Dec 2024 US FDA issued patent for NBI 921352
31 Dec 2024 Xenon Pharmaceuticals has patents pending for NBI 921352 in Worldwide

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com